Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 26 |
List of Tables | 24 | 3 |
List of Figures | 27 | 1 |
Introduction | 28 | 1 |
Global Markets Direct Report Coverage | 28 | 1 |
Tuberculosis Overview | 29 | 1 |
Therapeutics Development | 30 | 2 |
Pipeline Products for Tuberculosis Overview | 30 | 1 |
Pipeline Products for Tuberculosis Comparative Analysis | 31 | 1 |
Tuberculosis Therapeutics under Development by Companies | 32 | 5 |
Tuberculosis Therapeutics under Investigation by Universities/Institutes | 37 | 3 |
Tuberculosis Pipeline Products Glance | 40 | 4 |
Late Stage Products | 40 | 1 |
Clinical Stage Products | 41 | 1 |
Early Stage Products | 42 | 1 |
Unknown Stage Products | 43 | 1 |
Tuberculosis Products under Development by Companies | 44 | 7 |
Tuberculosis Products under Investigation by Universities/Institutes | 51 | 5 |
Tuberculosis Companies Involved in Therapeutics Development | 56 | 64 |
Abera Bioscience AB | 56 | 1 |
Akthelia Pharmaceuticals Limited | 57 | 1 |
Alvogen Korea Co., Ltd. | 58 | 1 |
Anacor Pharmaceuticals, Inc. | 59 | 1 |
Archivel Farma S.L. | 60 | 1 |
AstraZeneca Plc | 61 | 1 |
Beech Tree Labs, Inc. | 62 | 1 |
BioDiem Ltd | 63 | 1 |
BioLingus AG | 64 | 1 |
Biomar Microbial Technologies | 65 | 1 |
Bioversys AG | 66 | 1 |
Celgene Corporation | 67 | 1 |
Cellceutix Corporation | 68 | 1 |
Chongqing Zhifei Biological Products Co., Ltd. | 69 | 1 |
Crestone, Inc. | 70 | 1 |
Dafra Pharma International Ltd. | 71 | 1 |
Daiichi Sankyo Company, Limited | 72 | 1 |
Demuris Limited | 73 | 1 |
Eisai Co., Ltd. | 74 | 1 |
Eli Lilly and Company | 75 | 1 |
Ensol Biosciences Inc. | 76 | 1 |
EpiVax, Inc. | 77 | 1 |
FIT Biotech Oy | 78 | 1 |
GangaGen Inc. | 79 | 1 |
GlaxoSmithKline Plc | 80 | 1 |
Globeimmune, Inc. | 81 | 1 |
Hager Biosciences, LLC | 82 | 1 |
Hsiri Therapeutics LLC | 83 | 1 |
Imaxio SA | 84 | 1 |
Immunitor, Inc. | 85 | 1 |
ImmunoBiology Limited | 86 | 1 |
Inovio Pharmaceuticals, Inc. | 87 | 1 |
Johnson &Johnson | 88 | 1 |
Lakewood-Amedex Inc | 89 | 1 |
Lipotek Pty Ltd. | 90 | 1 |
Matinas BioPharma Holdings, Inc. | 91 | 1 |
Microbion Corporation | 92 | 1 |
Microbiotix, Inc. | 93 | 1 |
NEARMEDIC PLUS, Ltd | 94 | 1 |
Novartis AG | 95 | 1 |
NovoBiotic Pharmaceuticals, LLC | 96 | 1 |
Otsuka Holdings Co., Ltd. | 97 | 1 |
QureTech Bio AB | 98 | 1 |
Recce Pty Ltd | 99 | 1 |
Rodos BioTarget GmbH | 100 | 1 |
Sanofi | 101 | 1 |
Sanofi Pasteur SA | 102 | 1 |
Sarepta Therapeutics, Inc. | 103 | 1 |
Sequella, Inc. | 104 | 1 |
Shionogi &Co., Ltd. | 105 | 1 |
Sphaera Pharma Pvt. Ltd. | 106 | 1 |
Spring Bank Pharmaceuticals, Inc. | 107 | 1 |
Takeda Pharmaceutical Company Limited | 108 | 1 |
TetraLogic Pharmaceuticals | 109 | 1 |
TGV-Laboratories | 110 | 1 |
Theravectys SA | 111 | 1 |
Tomegavax, Inc. | 112 | 1 |
Transgene SA | 113 | 1 |
TVAX Biomedical, Inc. | 114 | 1 |
Univalue Valorizacion, S.L. | 115 | 1 |
Vaccibody AS | 116 | 1 |
Vakzine Projekt Management GmbH | 117 | 1 |
Vaxil Bio Therapeutics Ltd. | 118 | 1 |
Vichem Chemie Research Ltd. | 119 | 1 |
Tuberculosis Therapeutics Assessment | 120 | 12 |
Assessment by Monotherapy Products | 120 | 1 |
Assessment by Combination Products | 121 | 1 |
Assessment by Target | 122 | 3 |
Assessment by Mechanism of Action | 125 | 3 |
Assessment by Route of Administration | 128 | 2 |
Assessment by Molecule Type | 130 | 2 |
Drug Profiles | 132 | 234 |
(HIV + tuberculosis) vaccine Drug Profile | 132 | 1 |
(leprosy + pulmonary tuberculosis) vaccine Drug Profile | 133 | 2 |
Ab-02 Drug Profile | 135 | 1 |
AKT-10081 Drug Profile | 136 | 1 |
aldesleukin Drug Profile | 137 | 1 |
AM-009 Drug Profile | 138 | 1 |
AST-1753 Drug Profile | 139 | 1 |
Bacterial PPMO Drug Profile | 140 | 1 |
BBH-7 Drug Profile | 141 | 1 |
BDM-I Drug Profile | 142 | 3 |
bedaquiline fumarate Drug Profile | 145 | 4 |
birinapant Drug Profile | 149 | 7 |
bladder cancer + pertussis + tuberculosis vaccine Drug Profile | 156 | 1 |
BTL-slo Drug Profile | 157 | 1 |
BTP-15 Drug Profile | 158 | 1 |
BV-6481 Drug Profile | 159 | 1 |
capreomycin sulfate Drug Profile | 160 | 1 |
CC-11050 Drug Profile | 161 | 1 |
clofazimine Drug Profile | 162 | 1 |
CPZEN-45 Drug Profile | 163 | 1 |
CWGNC-41 Drug Profile | 164 | 1 |
DAR-901 Drug Profile | 165 | 1 |
DC-159a Drug Profile | 166 | 1 |
delamanid Drug Profile | 167 | 2 |
DF-152 Drug Profile | 169 | 1 |
EDE-1203 Drug Profile | 170 | 1 |
FS-1 Drug Profile | 171 | 1 |
GI-19000 Drug Profile | 172 | 1 |
GSK-070 Drug Profile | 173 | 1 |
GSK-147 Drug Profile | 174 | 1 |
GSK-3011724A Drug Profile | 175 | 1 |
GSK-692342 Drug Profile | 176 | 2 |
H-64 Drug Profile | 178 | 1 |
Hesed-1000 Drug Profile | 179 | 1 |
HG-85A Drug Profile | 180 | 1 |
HG-85A/B Drug Profile | 181 | 1 |
HG856-A Drug Profile | 182 | 1 |
HG856-BCG Drug Profile | 183 | 1 |
HG856-SeV Drug Profile | 184 | 1 |
HT-04 Drug Profile | 185 | 1 |
ID-93 Drug Profile | 186 | 2 |
IMX-313-TB Drug Profile | 188 | 1 |
infectious disease vaccine Drug Profile | 189 | 1 |
interleukin 2 Drug Profile | 190 | 1 |
KKL-35 Drug Profile | 191 | 1 |
lassomycin Drug Profile | 192 | 1 |
LCB-010371 Drug Profile | 193 | 2 |
Lipovax-Flic-TB Drug Profile | 195 | 1 |
MDN-0080 Drug Profile | 196 | 1 |
MDN-0096 Drug Profile | 197 | 1 |
MT-3001 Drug Profile | 198 | 1 |
MTbuVax Drug Profile | 199 | 1 |
MTBVAC-01 Drug Profile | 200 | 1 |
MVA-85A Drug Profile | 201 | 3 |
NC-00094221 Drug Profile | 204 | 1 |
ND-09759 Drug Profile | 205 | 1 |
NITD-304 Drug Profile | 206 | 1 |
NITD-349 Drug Profile | 207 | 1 |
NITD-916 Drug Profile | 208 | 1 |
Novo-23 Drug Profile | 209 | 1 |
Nu-3 Drug Profile | 210 | 2 |
P-128 Drug Profile | 212 | 1 |
PBTZ-169 Drug Profile | 213 | 1 |
Peptides for Tuberculosis Drug Profile | 214 | 1 |
PMX-10072 Drug Profile | 215 | 1 |
pretomanid Drug Profile | 216 | 3 |
pulmonary tuberculosis vaccine Drug Profile | 219 | 1 |
Q-203 Drug Profile | 220 | 1 |
QR-109 Drug Profile | 221 | 1 |
RBT-10 Drug Profile | 222 | 1 |
RSQ-15 Drug Profile | 223 | 1 |
RUTI Drug Profile | 224 | 1 |
S-006830 Drug Profile | 225 | 1 |
SB-9922 Drug Profile | 226 | 1 |
SBP-17GA20 Drug Profile | 227 | 1 |
SEQ-9 Drug Profile | 228 | 1 |
Small Molecule 2 for Tuberculosis Drug Profile | 229 | 1 |
Small Molecule 3 for Tuberculosis Drug Profile | 230 | 1 |
Small Molecule 4 for Tuberculosis Drug Profile | 231 | 1 |
Small Molecule for Malaria and Bacterial Infections Drug Profile | 232 | 1 |
Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis Drug Profile | 233 | 1 |
Small Molecule for Staphylococcus Aureus Infections and Tuberculosis Drug Profile | 234 | 1 |
Small Molecule for Tuberculosis Drug Profile | 235 | 1 |
Small Molecule for Tuberculosis Drug Profile | 236 | 1 |
Small Molecule for Tuberculosis Drug Profile | 237 | 1 |
Small Molecule for Tuberculosis Drug Profile | 238 | 1 |
Small Molecule to Inhibit Beta Sliding Clamp for Tuberculosis Drug Profile | 239 | 1 |
Small Molecule to Inhibit CysK1 for Tuberculosis Drug Profile | 240 | 1 |
Small Molecule to Inhibit DNA Gyrase for Tuberculosis Drug Profile | 241 | 1 |
Small Molecule to Inhibit DNA-Directed RNA Polymerase Subunit Beta and HIV Integrase for HIV and Tuberculosis Drug Profile | 242 | 1 |
Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis Drug Profile | 243 | 1 |
Small Molecule to Inhibit MmpL3 for Tuberculosis Drug Profile | 244 | 1 |
Small Molecule to Inhibit Pks13 for Tuberculosis Drug Profile | 245 | 1 |
Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis Drug Profile | 246 | 1 |
Small Molecule to Target InhA for Tuberculosis Drug Profile | 247 | 1 |
Small Molecule to Target Mycobacterial Biofilms for Tuberculosis Drug Profile | 248 | 1 |
Small Molecules 2 for Tuberculosis Drug Profile | 249 | 1 |
Small Molecules for Infectious Disease Drug Profile | 250 | 1 |
Small Molecules for Infectious Diseases Drug Profile | 251 | 1 |
Small Molecules for Infectious Diseases Drug Profile | 252 | 1 |
Small Molecules for Infectious Diseases Drug Profile | 253 | 1 |
Small Molecules for Multiresistant Tuberculosis Drug Profile | 254 | 1 |
Small Molecules for Tuberculosis Drug Profile | 255 | 1 |
Small Molecules for Tuberculosis Drug Profile | 256 | 1 |
Small Molecules for Tuberculosis Drug Profile | 257 | 1 |
Small Molecules for Tuberculosis Drug Profile | 258 | 1 |
Small Molecules for Tuberculosis Drug Profile | 259 | 1 |
Small Molecules for Tuberculosis Drug Profile | 260 | 1 |
Small Molecules for Tuberculosis Drug Profile | 261 | 1 |
Small Molecules for Tuberculosis Drug Profile | 262 | 1 |
Small Molecules for Tuberculosis Drug Profile | 263 | 1 |
Small Molecules for Tuberculosis Drug Profile | 264 | 1 |
Small Molecules for Tuberculosis Drug Profile | 265 | 1 |
Small Molecules for Tuberculosis Drug Profile | 266 | 1 |
Small Molecules for Tuberculosis Drug Profile | 267 | 1 |
Small Molecules for Tuberculosis Drug Profile | 268 | 1 |
Small Molecules for Tuberculosis Drug Profile | 269 | 1 |
Small Molecules for Tuberculosis Drug Profile | 270 | 1 |
Small Molecules for Tuberculosis and Mycobacterial Infections Drug Profile | 271 | 1 |
Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections Drug Profile | 272 | 1 |
Small Molecules to Antagonize Folate Receptor for Tuberculosis Drug Profile | 273 | 1 |
Small Molecules to Inhibit 16S rRNA for Tuberculosis Drug Profile | 274 | 1 |
Small Molecules to Inhibit 50S RNA for Bacterial Infections and Tuberculosis Drug Profile | 275 | 1 |
Small Molecules to Inhibit Alanine Racemase for Tuberculosis and MRSA Infections Drug Profile | 276 | 1 |
Small Molecules to Inhibit APS Reductase for Tuberculosis Drug Profile | 277 | 1 |
Small Molecules to Inhibit ATP Synthesis for Tuberculosis Drug Profile | 278 | 1 |
Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis Drug Profile | 279 | 1 |
Small Molecules to Inhibit DHFR for Tuberculosis Drug Profile | 280 | 1 |
Small Molecules to Inhibit DNA gyrase and AddAB /RecBCD helicase for Tuberculosis Drug Profile | 281 | 1 |
Small Molecules to Inhibit DNA Gyrase for Tuberculosis Drug Profile | 282 | 1 |
Small Molecules to Inhibit DNA GyrB for Tuberculosis Drug Profile | 283 | 1 |
Small Molecules to Inhibit DprE1 for Tuberculosis Drug Profile | 284 | 1 |
Small Molecules to Inhibit DprE1 for Tuberculosis Drug Profile | 285 | 1 |
Small Molecules to Inhibit DXR for Malaria and Tuberculosis Drug Profile | 286 | 1 |
Small Molecules to Inhibit FtsZ for Tuberculosis Drug Profile | 287 | 1 |
Small Molecules to Inhibit Hypoxanthine Phosphoribosyltransferase for Malaria and Tuberculosis Drug Profile | 288 | 1 |
Small Molecules to Inhibit InhA for Tuberculosis Drug Profile | 289 | 1 |
Small Molecules to Inhibit L,D-Transpeptidase for Tuberculosis Drug Profile | 290 | 1 |
Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis Drug Profile | 291 | 1 |
Small Molecules to Inhibit MmpL3 for Tuberculosis Drug Profile | 292 | 1 |
Small Molecules to Inhibit PBPs for Tuberculosis Drug Profile | 293 | 1 |
Small Molecules to Inhibit Protein Kinase B for Tuberculosis Drug Profile | 294 | 1 |
Small Molecules to Inhibit RelMtb for Tuberculosis Drug Profile | 295 | 1 |
Small Molecules to Inhibit RNA Polymerase for Bacterial Infections and Tuberculosis Drug Profile | 296 | 1 |
Small Molecules to Inhibit RNA Polymerase for Tuberculosis Drug Profile | 297 | 1 |
Small Molecules to Inhibit RNA Polymerase for Tuberculosis Drug Profile | 298 | 1 |
Small Molecules to Inhibit RNA Polymerase for Tuberculosis Drug Profile | 299 | 1 |
Small Molecules to Inhibit RNA Polymerase for Tuberculosis and Staphylococcus Aureus Infections Drug Profile | 300 | 1 |
Small Molecules to Inhibit Siderophores for Tuberculosis Drug Profile | 301 | 1 |
Small Molecules to Inhibit UGM for Tuberculosis and Microbial Infections Drug Profile | 302 | 1 |
Small Molecules to Target RNA Polymerase for Tuberculosis Drug Profile | 303 | 1 |
SPR-113 Drug Profile | 304 | 1 |
SQ-109 Drug Profile | 305 | 3 |
SQ-609 Drug Profile | 308 | 1 |
SQ-641 Drug Profile | 309 | 1 |
SRI-58 Drug Profile | 310 | 1 |
SSIH-56IC31 Drug Profile | 311 | 2 |
sutezolid Drug Profile | 313 | 1 |
T-BioVax Drug Profile | 314 | 1 |